Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Nov 06, 2019	CareDx at ASN Kidney Week AlloSure highlighted at the American Society of Nephrology Conference BRISBANE, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Nov 04, 2019	CareDx Advances Patient Care with AlloSure 3.0 CareDx drives continued transplant focused improvements to AlloSure BRISBANE, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare	View HTML
Toggle Summary Oct 31, 2019	CareDx Reports Third Quarter 2019 Results AlloSure momentum drives 60% third quarter revenue growth BRISBANE, Calif. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare	View HTML
Toggle Summary Oct 17, 2019	CareDx to Announce Third Quarter 2019 Financial Results on October 31st, 2019 BRISBANE, Calif. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML
Toggle Summary Oct 08, 2019	CareDx Participates in Transplant Roundtable with Senator Durbin CareDx joins UI Health and NKF to meet with Senator Durbin and advocate for action on anti-rejection drug coverage for kidney transplant patients BRISBANE, Calif. , Oct. 08, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery,	View HTML
Toggle Summary Sep 26, 2019	CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor CareDx protects transplantation innovation by enforcing patent protection BRISBANE, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Sep 24, 2019	CareDx Adds HistoMap To Testing Portfolio CareDx partners with NanoString to improve precision of transplant biopsies BRISBANE, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Sep 23, 2019	CareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication Artificial Intelligence algorithm predicts long-term kidney transplant outcomes BRISBANE, Calif. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated,	View HTML
Toggle Summary Sep 20, 2019	CareDx Launches AlloSeq® Tx 17 at ASHI/BANFF Meeting AlloSeq Tx 17 is a best in class HLA typing solution with the most comprehensive sequencing and easiest workflow BRISBANE, Calif. , Sept. 20, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of	View HTML
Toggle Summary Sep 18, 2019	First Patient Enrolled in Landmark CareDx OKRA Registry CareDx drives best in class 4,000 transplant patient registry with KOAR and OKRA BRISBANE, Calif. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated,	View HTML